In a recent study, the authors showed that melittin, an anti-inflammatory drug, inhibits the proliferation and migration of castration-resistant prostate cancer cells by downregulating the IL-17 signaling pathway [42]. The gene discussed is IL17A; the disease is Familial prostate cancer.